m
Recent Posts
Connect with:
Friday / November 8.
HomeminewsUrine Diagnostic Detects River Blindness Parasite

Urine Diagnostic Detects River Blindness Parasite

A new urine diagnostic, which took ten years to develop, can detect the parasitic worms that cause onchocerciasis – or river blindness – a tropical disease that afflicts 18 to 120 million people worldwide.

Described in the journal ACS Infectious Diseases, the new, non-invasive test may provide an inexpensive way to determine, in real time, whether a person has an infection, which would give public health officials and doctors critical information for tracking outbreaks and treating current infections.

“River blindness affects individuals both in Africa and Latin America, and because many of these endemic regions are difficult to access, what is needed in the field is an inexpensive point of care means to monitor the disease,” said Prof. Kim Janda, a member of the Skaggs Institute for Chemical Biology at Scripps Research, where the work has been undertaken.

River blindness is a filarial disease, like elephantiasis, and occurs when the parasitic worm Onchocerca volvulus takes up residence in the skin. Adult worms pump out babies (microfilaria) at an alarming rate, which are ultimately re-spread by blackfly bites. The microfilariae can migrate to the eye and die, releasing toxins and causing inflammation. People with the disease will slowly go blind without medical intervention.

Prof. Janda said onchocerciasis monitoring and evaluation are especially necessary steps for people leading elimination efforts. To know if these efforts are working, doctors need to be able to show when disease transmission has been interrupted. The current gold standard for detecting the parasitic worms is a “skin snip” biopsy. However, snips are generally insensitive indicators of infection, and the sensitivity of the skin snip decreases as the density of microfilaria in the skin decreases. Other tests cannot distinguish between past and current infections.

“River blindness is a filarial disease, like elephantiasis, and occurs when the parasitic worm Onchocerca volvulus takes up residence in the skin”

Currently, onchocerciasis elimination programs rely primarily on mass drug administration of the therapy Ivermectin to suppress and eventually eliminate transmission of Onchocerca volvulus. Yet, without a means to evaluate if an infection is ongoing, it’s hard to assess if prevention efforts are working – and if it’s safe for people to stop taking medication.

The new lateral flow assay took over 10 years to develop, but it is now ready for manufacturing and testing in the field. The key to the assay’s success was in the making of designer antibodies to detect a unique biomarker that only shows up when a human host has metabolised a worm neurotransmitter called tyramine. Humans then secrete this biomarker in urine.

A negative on the dipstick test shows a coloured line in the test. A positive shows no lines.

Unlike the skin snip biopsy, Prof. Janda said this non-invasive test is the first to use a metabolite produced by adult worms. Moreover, the dipstick’s inexpensive design, coupled with smartphone apps, would offer automatic image processing, which ultimately could translate to address critical gaps in the surveillance and treatment of river blindness.

Authors of the study, “Non-Invasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis Infection,” were first author Ryan Shirey, Daniel Globisch, Lisa Eubanks and Mark S. Hixon of Scripps Research.

The work was supported by a donation by John Moore to The Worm Institute of Research and Medicine (WIRM) of Scripps Research, the Skaggs Institute for Chemical Biology, and by the Institute for Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Germany, as part of a consortium grant funded by the Bill and Melinda Gates Foundation (grant OPP1083888).

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.